FDA approves UCB’s drug to treat epilepsy-related seizures

(Reuters) – The U.S. Food and Drug Administration (FDA) approved Belgian drugmaker UCB SA’s drug as an add-on therapy to treat partial seizures caused by epilepsy. The FDA approval comes nearly two months after the European health regulators recommended approval of the drug, Briviact, in Europe. The Belgian drugmaker has been active in epilepsy drug research and development for over 20 years and treating the disease forms an important plank of its business.
Go to Source